Irish clinical trials group ICON today reported a 41 per cent rise in net revenues for the fourth quarter of this year.
Net revenues for the quarter were $31.5 million, compared with $22.4 million for the same quarter last year.
Net revenues for the full year were up 44 per cent to $116.2 million from $80.8 million.
Income from operations rose 42 per cent to $3.4 million, compared $2.4 million reported on a pro-forma basis for the fourth quarter last year.
Diluted earnings per share was 25 cents, up 25 per cent on last year’s figure. For the full year, diluted earnings per share was 92 cents - a rise of 31 per cent.
ICON Chairman Dr Ronan Lambe said: "Fiscal 2001 has been another excellent year for ICON. Business flows have been strong leading to record new business awards, margins have been continuing to increase and our acquisitions have performed well."
"From a strategic perspective we are very confident that ICON's growth model continues to be valid, and we look forward with confidence to another year of continuing growth and profitability."
